摘要
目的检测系统性红斑狼疮(SLE)患者血清可溶性人类白细胞抗原-G(sHLA-G)水平以及外周血CD3+T细胞上HLA-G的表达水平,并分析其与Th1/Th2细胞分化的关系,探讨其在系统性红斑狼疮发病机制中的可能作用。方法选取60例SLE患者作为SLE组和60例健康体检者作为健康组,分别采用流式细胞术和酶联免疫吸附试验检测外周血CD3^+HLA-G^+T亚群的表达情况以及血清sHLA-G的表达水平;同时检测血清IFN-γ、IL-10的水平。结果SLE患者CD3^+HLA-G^+T百分比较健康组高(P<0.01);SLE患者血清sHLA-G水平显著高于健康组(P<0.01),SLE中的Th2型细胞因子IL-10显著高于健康组(P<0.01);mHLA-G和sHLA-G的变化与IL-10呈正相关(r值分别为0.507、0.706,P=0.001)(P<0.01)。结论SLE患者的CD3+HLA-G+T亚群和sHLA-G显著增加,可能参与了SLE的发病,并可作为SLE的诊断标志物。
Objective To study the clinical significance of CD3+HLA-G+T cell in peripheral blood and the soluble form of HLA-G(sHLA-G)in serum with systemic lupus erythematosus(SLE),and its effect on the Th1/Th2 imbalance in systemic lupus erythematosus.Methods The study included 60 SLE patients and 60 healthy controls.Flow cytometry analysis was used to detect the percentages of CD3^+HLA-G^+T cells in peripheral blood samples,enzyme-linked immunosorbent assay was used to detect the serum concentration of sHLA-G,IFN-γand IL-10 production in SLE patients.Results The median percentages of CD3^+HLA-G^+T cells was increased in SLE than healthy control,with the difference statistically significant(P<0.01);serum sHLA-G level of SLE patients was significantly higher than that of the healthy group(P<0.01).The Th2-type cytokine,IL-10,in SLE patients was significantly higher than that of the healthy group(P<0.01).The changes of mHLA-G and sHLA-G were positively correlated with IL-10(r=0.507,r=0.706,P=0.001),and the difference was statistically significant(P<0.01).Conclusion The level of CD3+HLA-G+T cells in peripheral blood and sHLA-G in serum were significantly increase in SLE patients,which suggested that HLA-G plays roles in the lesion of SLE,and it could be used as a diagnostic marker of SLE.
作者
华馨
潘红
施敏
HUA Xin;PAN Hong;SHI Min(Clinical Laboratory,HwaMei Hospital,University of Chinese Academy of Science Ningbo Institute of Life and Health Industry,University of Chinese Academy of Sciences,Ningbo,Zhejiang 315010,China)
出处
《中国卫生检验杂志》
CAS
2020年第15期1848-1851,共4页
Chinese Journal of Health Laboratory Technology
基金
宁波市公益基金资助(LY19H160011)。